For the quarter ending 2026-03-31, HALO had $175,588K increase in cash & cash equivalents over the period. $176,337K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Realized gain on marketable securities | - | 244 | -47 | -26 |
| Net income | 150,049 | -141,591 | 175,225 | 283,255 |
| Loss on disposal of equipment | - | -2,621 | 0 | 0 |
| Share-based compensation | 16,637 | 16,571 | 12,160 | 22,834 |
| Depreciation and amortization | 4,221 | 3,304 | 2,658 | 5,427 |
| Amortization of intangible assets | 29,512 | 23,376 | 17,762 | 35,524 |
| Amortization of debt discount | 2,245 | 1,950 | 1,858 | 3,698 |
| Contingent liability fair value measurement adjustment | - | 0 | - | - |
| Accretion of premium on marketable securities, net | 30 | 96 | 357 | 2,843 |
| Lease payments recognized | -214 | -271 | -170 | -510 |
| Induced conversion expense related to 2027 and 2028 convertible notes | - | 5,477 | - | - |
| Deferred income taxes | -3,428 | 16,768 | -27,354 | 9,952 |
| Acquired in-process research and development expense | - | 284,887 | - | - |
| Impairment of intangible asset | - | 48,700 | - | - |
| Accounts receivable, net and contract assets | 19,547 | 90,483 | 29,696 | 7,884 |
| Inventories | -27,379 | -18,781 | 1,101 | 15,126 |
| Prepaid expenses and other assets | 9,108 | -28,424 | 20,319 | 41,063 |
| Accounts payable and accrued expenses | -24,922 | 33,849 | -7,164 | -20,474 |
| Net cash provided by operating activities | 180,078 | 219,029 | 178,597 | 253,932 |
| Purchases of marketable securities | 8,846 | 0 | 4,956 | 242,399 |
| Proceeds from sales and maturities of marketable securities | - | 722,248 | - | - |
| Acquisition of business, net of cash acquired | - | 725,965 | - | - |
| Proceeds from sales and maturities of marketable securities | -439,873 | - | 209,595 | 239,278 |
| Acquisition of in-process research and development, net of cash acquired | - | 287,771 | - | - |
| Proceeds from working capital adjustments on acquisition | 710 | - | - | - |
| Purchases of property and equipment | 3,741 | 1,427 | 3,030 | 2,513 |
| Net cash used in investing activities | -2,877 | -741,788 | 201,609 | -5,634 |
| Repayments of convertible notes-A2024Convertible Notes | - | 0 | - | - |
| Repayments of convertible notes-A0.25Convertible Senior Notes Due2027 | - | 595,425 | - | - |
| Repayments of convertible notes-A1.00Convertible Senior Notes Due2028 | - | 250,001 | - | - |
| Proceeds from convertible debt-A0.00Convertible Senior Notes Due2031 | - | 735,000 | - | - |
| Proceeds from convertible debt-A0.875Convertible Senior Notes Due2032 | - | 735,000 | - | - |
| Payment for the induced conversion of 2027 and 2028 convertible notes | - | 5,477 | - | - |
| Premium on repayment of convertible notes settled in cash-A0.25Convertible Senior Notes Due2027 | - | 78,132 | - | - |
| Premium on repayment of convertible notes settled in cash-A1.00Convertible Senior Notes Due2028 | - | 89,833 | - | - |
| Purchase of capped calls on 2031 convertible notes-A0.00Convertible Senior Notes Due2031 | - | 104,025 | - | - |
| Purchase of capped calls on 2031 convertible notes-A0.875Convertible Senior Notes Due2032 | - | 106,800 | - | - |
| Payment of debt issuance cost | - | 4,938 | - | - |
| Repurchase of common stock | - | 0 | 38,883 | 303,489 |
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | - | 4,146 | 16,481 | 1,202 |
| Taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plans | 1,613 | - | - | - |
| Net cash used in financing activities | -1,613 | 239,515 | -22,402 | -302,287 |
| Net increase in cash and cash equivalents | 175,588 | -283,244 | 357,804 | -53,989 |
| Cash and cash equivalents at beginning of period | 136,421 | 419,665 | 115,850 | - |
| Cash and cash equivalents at end of period | 312,009 | 136,421 | 419,665 | - |
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)